To examine variation rate of Non-HDL with KI1107 comparison Rosuvastatin monotherapy.

Study design:

Randomly assigned to two groups(KI1107 or Rosuvastatin monotherpy) after 4 weeks run-in period and prescribed KI1107 or Rosuvastatin for 8 weeks.

Inclusion criteria:

• Screening Visit

  • Age: 19-80
  • High risk for cardiovascular disease according to NCEP APT III
  • TG≥130mg/dL and 160mg/dL>LDL-C≥100mg/dL for subjects who were not taking statins for 4 weeks
  • 500mg/dL>TG≥200mg/dL and LDL-C<110mg/dL for subjects who were taking statins for 4 weeks

• Baseline Visit

  • 500mg/dL>TG≥200mg/dL
  • LDL-C<110mg/dL
  • Reduction of LDL-C dompairng screening visit

Exclusion criteria:

• The patient has histories of acute artery disease within 3 months
• The patient has histories of operation revasculatiation or aneurysm within 6 months
• The patient has histories of Unexplained myaliga or diagnosed myalgia or rhabdomyolysis
• The patient has histories of Effectable disease to the procedrue and clinical trial result